<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350701</url>
  </required_header>
  <id_info>
    <org_study_id>1911</org_study_id>
    <nct_id>NCT00350701</nct_id>
  </id_info>
  <brief_title>Effect of Androgel on Type 2 Diabetic Males With Hypogonadism</brief_title>
  <official_title>Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaleida Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is to study the effect of replacing testosterone on different inflammatory cells in type
      2 diabetics with low testosterone levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is an atherosclerotic, pro-inflammatory and pro-oxidative stress.
      Hypogonadism( low testosterone) is also associated with increased levels of inflammatory
      mediators and atherosclerosis.

      This project is about studying the effect of testosterone replacement on different
      inflammatory cells in blood and urine. It will also compare the dose dependent effect on
      inflammatory cells. This also involves comparing level of inflammation in hypogonadic
      diabetic males treated with testosterone with those not treated with any replacement therapy.

      This study involves applying AndroGel for 8 wks and studying effects during this time and
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To detect a difference in Nuclear Factor kB between AndroGel and placebo from baseline and at 8 weeks.</measure>
    <time_frame>8 weeks</time_frame>
    <description>measure effect of teststerone on inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of relative change from baseline in inflammatory mediators and reactive oxygen species generation after either AndroGel or placebo at week 8.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measures inflammation change with testosterone</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>androgel 5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>androgel 5g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>androgel 10g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>androgel 10g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>androgel</intervention_name>
    <description>androgel 5g</description>
    <arm_group_label>androgel 5g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>androgel 10g</intervention_name>
    <description>androgel 10g</description>
    <arm_group_label>androgel 10g</arm_group_label>
    <other_name>androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males with age 35-75 years inclusive.

          -  Evidence of hypogonadism: low free testosterone.

          -  Type 2 Diabetes

          -  People on stable doses of cholesterol lowering medications, blood pressure medications
             and multi-vitamins are allowed.

          -  If currently on testosterone replacement,testosterone treatment will be held for 8
             weeks.

          -  BP under control even if on medication.

        Exclusion Criteria:

          -  Coronary event or procedure in previous past 4 wks.

          -  High PSA

          -  H/O prostate cancer

          -  Hepatic or renal disease

          -  Participation in any other concurrent clinical trial

          -  Any other life- threatening , non cardiac disease.

          -  Uncontrolled BP

          -  Congestive heart failure

          -  High hemoglobin

          -  Use of investigational agent or therapeutic regimen within 30 days of study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaleida Health/Diabetes Endocrinology Center of WNY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes-Endocrinology Center of Western NY, 115 flint road</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2006</study_first_submitted>
  <study_first_submitted_qc>July 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2006</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaleida Health</investigator_affiliation>
    <investigator_full_name>Paresh Dandona, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>DM type 2</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Testosterone</keyword>
  <keyword>AndroGel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

